Clinical Report: CTLA-4/CD80 Interaction as a Biomarker for Predicting Outcomes

Overview

This study identifies CTLA-4/CD80 interaction states as predictive biomarkers for patient stratification in anti-PD-1/PD-L1 therapies for NSCLC based on observed data.

Background

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with immune checkpoint inhibitors (ICIs) improving survival outcomes but exhibiting variable response rates. Identifying reliable predictive biomarkers beyond PD-L1 expression is crucial for patient treatment strategies.

Data Highlights

Key Findings

• High PD-1/PD-L1 interaction predicts improved response rates in NSCLC patients.
• High CTLA-4/CD80 interaction correlates with improved overall and progression-free survival.
• Patients with high levels of both PD-1/PD-L1 and CTLA-4/CD80 interactions show the highest response rates.
• Neither biomarker predicts response to chemotherapy in lung adenocarcinoma patients.
• QF-Pro® platform effectively quantifies interaction states in FFPE samples.

Clinical Implications

The findings indicate that assessing CTLA-4/CD80 interactions may enhance patient stratification for ICI therapies in NSCLC.

Conclusion

The study highlights the potential of CTLA-4/CD80 interaction as a predictive biomarker for anti-PD-1/PD-L1 therapy in NSCLC.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Frontiers in Medicine — Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study
3. the asco post — Survival With Dual CTLA-4 and PD-L1/PD-1 Blockade in Advanced NSCLC
4. Frontiers in Oncology — LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy
5. International Journal of Infectious Diseases — CTLA-4 and CD154 expression on peripheral T cells as diagnostic biomarkers for pulmonary tuberculosis
6. Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study
7. Survival With Dual CTLA-4 and PD-L1/PD-1 Blockade in Advanced NSCLC
8. LAG3-centered multiplex immune profiling as a prognostic biomarker in hepatocellular carcinoma patients receiving Anti-PD-1 antibodies plus lenvatinib therapy
9. Guideline Topic Priorities - ASCO
10. Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction - PubMed
11. Frontiers | Immune Checkpoint Crosstalk: CTLA-4/CD80 Engagement as a Predictor of Anti-PD-1/PD-L1 Therapy Outcome in NSCLC